A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction.
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Colestipol (Primary) ; Ezetimibe (Primary) ; Niacin (Primary) ; HMG-CoA reductase inhibitors
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- 05 Nov 2005 New trial record.